 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...169170171172173174175176177178179...208209» |
- || SHR2285 / Jiangsu Hengrui Pharma
Trial completion date, Trial initiation date, Trial primary completion date: The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects (clinicaltrials.gov) - Aug 7, 2020
P1, N=24, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial completion date: Jul 2020 --> Dec 2020 | Initiation date: Jan 2020 --> Aug 2020 | Trial primary completion date: Apr 2020 --> Sep 2020
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Male mammary gland development after apatinib therapy in advanced gastric cancer: A case report. (Pubmed Central) - Aug 7, 2020
Trial completion date: Jul 2020 --> Dec 2020 | Initiation date: Jan 2020 --> Aug 2020 | Trial primary completion date: Apr 2020 --> Sep 2020 This case report is the first to report the case of male mammary gland development after oral apatinib.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC (clinicaltrials.gov) - Aug 7, 2020
P2, N=40, Recruiting, Sponsor: Hebei Medical University Fourth Hospital
This case report is the first to report the case of male mammary gland development after oral apatinib. Not yet recruiting --> Recruiting
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Enrollment open, Trial initiation date: Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor (clinicaltrials.gov) - Aug 7, 2020
P2, N=180, Recruiting, Sponsor: Hebei Medical University Fourth Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Jul 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: LungMate-003: Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 7, 2020
P2, N=99, Recruiting, Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Jul 2020 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. (clinicaltrials.gov) - Aug 6, 2020
P3, N=45, Not yet recruiting, Sponsor: Fuzhou General Hospital
- || famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P1 trial: A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on Famitinib (clinicaltrials.gov) - Aug 6, 2020
P1, N=21, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 6, 2020
P2, N=117, Recruiting, Sponsor: Fudan University
- | AiTan (rivoceranib) / HLB Bio Group
New trial: Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults (clinicaltrials.gov) - Aug 6, 2020
P=N/A, N=29, Recruiting, Sponsor: Beijing Sanbo Brain Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children (clinicaltrials.gov) - Aug 6, 2020
P2, N=44, Recruiting, Sponsor: Beijing Sanbo Brain Hospital
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Observational data, Journal: Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study. (Pubmed Central) - Aug 6, 2020
No treatment-related grade 4 or 5 adverse events were recorded. Apatinib revealed to have antitumour activity in unresectable ICC patients, with manageable toxicities, and thus might be used as a new treatment option for patients with unresectable ICC.
- || AiTan (rivoceranib) / HLB Bio Group, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. (Pubmed Central) - Aug 6, 2020
The results of the multivariate analysis demonstrated that liver tumor load [hazard ratio (HR): 3.653, 95% CI: 2.047, 5.965, p < 0.001] and extrahepatic spread (HR: 0.303, 95% CI: 0.231, 0.778, p = 0.003) were independent predictors of OS after apatinib treatment. This study showed that subsequent apatinib treatment may improve survival outcomes compared with supportive care for patients with sorafenib-resistant, advanced hepatitis B virus (HBV)-related HCC, especially for patients who have a lower liver tumor load and extrahepatic spread.
- || simvastatin / Generic mfg., AiTan (rivoceranib) / HLB Bio Group
PK/PD data, Preclinical, Journal: Effects of multidose simvastatin co-administration on pharmacokinetic profile of apatinib in rats by UPLC-MS/MS. (Pubmed Central) - Aug 5, 2020
Apatinib concentrations of rat plasma samples were detected by UPLC-MS/MS. Pharmacokinetic parameters were calculated using non compartmental methods.Co-administration of SV for 7 days significantly increased AUC, AUC and C of apatinib by 2.4-fold, 2.4-fold and 2.7-fold, while decreasing Vz/F and CLz/F by 81.7% and 73.9%.These findings suggest that concomitant administration of SV with 7 days may have inhibited the metabolism of apatinib in rats.
- | VT-1598 / Mycovia Pharma, otesaconazole (VT-1161) / Mycovia Pharma, fluconazole / Generic mfg.
Journal: Impact of the major Candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161. (Pubmed Central) - Aug 4, 2020
Of the three major transporter genes regulated by Pdr1, CDR1 deletion resulted in the largest MIC reductions for all agents tested, while PDH1 and SNQ2 deletion individually impacted MICs very little. Overall, both VT-1161 and VT-1598 have comparable activities to the available triazoles, and decreased susceptibility to these tetrazoles in C. glabrata is driven by many of the same known resistance mechanisms.
- | AiTan (rivoceranib) / HLB Bio Group, etoposide IV / Generic mfg.
Retrospective data, Journal: Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study. (Pubmed Central) - Aug 4, 2020
Most adverse events of this combined therapy were mild and tolerable. Severe mucositis oral was not rare, which needs more precautions.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. (Pubmed Central) - Aug 1, 2020
Fourteen patients emerged with grade 3 apatinib-related adverse events. The efficacy of TACE-apatinib for patients with advanced HCC was inspiring, and the side effects of apatinib were tolerable.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: The synergistic anti-tumor effect of schisandrin B and apatinib. (Pubmed Central) - Jul 31, 2020
The results were confirmed by western blot analysis of the proteins MMP-9, and Bax caspase-9, and -12. These results suggest that combining apatinib and Sch.B is an effective therapeutic strategy for preventing GC progression.
- || AiTan (rivoceranib) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
Biomarker, Clinical, Journal: Malignant Gastrointestinal Neuroectodermal Tumor: Clinicopathologic, Immunohistochemical, and Molecular Analysis of 19 Cases. (Pubmed Central) - Jul 31, 2020
In conclusion, GNET has distinctive morphologic, immunohistochemical, and molecular genetic features and should be distinguished from other gastrointestinal tract malignancies. Apatinib and anlotinib might be effective for the treatment of advanced GNET and could prolong patient survival.
- | AiTan (rivoceranib) / HLB Bio Group
Preclinical, Journal: The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo. (Pubmed Central) - Jul 29, 2020
Apatinib and anlotinib might be effective for the treatment of advanced GNET and could prolong patient survival. The efficacy of apatinib combination is better than that of monotherapy, and there is no significant difference in toxicity of important organs, which suggests the feasibility of a combination of apatinib in the treatment of non-small cell lung cancer.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib-loaded nanoparticles inhibit tumor growth and angiogenesis in a model of melanoma. (Pubmed Central) - Jul 29, 2020
The protein levels of VEGFR-2, phosphorylated (p)-VEGFR-2 and p-ERK1/2 in tumor tissues were inhibited by Apa/p NP treatment, as detected by Western blot. The results of this study suggested that Apa/p NPs could inhibit the growth of melanoma tumors by inhibiting the phosphorylation and expression of VEGFR-2 and downstream ERK1/2, providing a theoretical basis for the clinical application of Apatinib in the treatment of melanoma.
- |||||| AiTan (rivoceranib) / HLB Bio Group
Enrollment open, BRCA Biomarker, PARP Biomarker: FABULOUS: A Study of Fluzoparib (clinicaltrials.gov) - Jul 26, 2020
P3, N=474, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
The results of this study suggested that Apa/p NPs could inhibit the growth of melanoma tumors by inhibiting the phosphorylation and expression of VEGFR-2 and downstream ERK1/2, providing a theoretical basis for the clinical application of Apatinib in the treatment of melanoma. Not yet recruiting --> Recruiting
- || edralbrutinib (TG-1701) / TG Therap
Trial completion: A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects (clinicaltrials.gov) - Jul 26, 2020
P1, N=28, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial, Real-world evidence: Camrelizumab Utilization on Patients With Advanced Liver Cancer (clinicaltrials.gov) - Jul 26, 2020
P=N/A, N=1000, Not yet recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P2 trial: MUKDEN 01: Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial (clinicaltrials.gov) - Jul 26, 2020
P2, N=89, Not yet recruiting, Sponsor: Shengjing Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: CARD: Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL (clinicaltrials.gov) - Jul 26, 2020
P1/2, N=33, Recruiting, Sponsor: Huiqiang Huang
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
#Novaliq Gmbh : A disruptive delivery platform or an health risk ? Take a look here https://t.co/Ff7z6we1KW #Geuder #Fluoron #f4h5 #f6h8 #NOV03 #perfluorohexyloctane (Twitter) - Jul 25, 2020
- || fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine
Clinical, P1 data, Journal, BRCA Biomarker, PARP Biomarker: Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. (Pubmed Central) - Jul 24, 2020
The MTD of fluzoparib was 150 mg bid in advanced solid malignancies. Fluzoparib demonstrated single-agent antitumor activity in BC and OC, particularly in BRCA and platinum-sensitive OC.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Application of anti-PD1 drugs before or during thoracic radiotherapy increases the incidence of radiation pneumonia compared to the application after radiotherapy (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2643;
Legal entity responsible for the study: Xiangzhi Zhu. Funding: Has not received any funding.
- AiTan (rivoceranib) / HLB Bio Group, irinotecan / Generic mfg.
[VIRTUAL] Apatinib combined with irinotecan in the treatment of small cell lung cancer: A phase II, single-arm, prospective study (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2551;
Funding: Has not received any funding. Clinical trial identification: ChiCTR1800018642 2018/9/30.
- topotecan / Generic mfg., AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] The efficacy of apatinib plus topotecan as laterline therapy for advanced small cell lung cancer (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2550;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- [VIRTUAL] Plinabulin (Plin) is a more favorable option for the prevention of chemotherapy induced neutropenia (CIN) than pegfilgrastim (Peg) during the COVID-19 pandemic (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2463;
P3
Study 106 in Breast cancer pts given High FN Risk Doc +Doxorubicin 50 mg/m2 + Cyclophosphamide 50mg/m2 (TAC)...Funding: BeyondSpring Pharma, Inc. Clinical trial identification: NCT03102606, NCT03294577.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Anti-angiogenic therapy induced pneumothorax (AIP) is associated with long-lasting response and survival benefit for paediatric and young adult sarcoma (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2412;
Methods A total of 131 sarcoma pts were treated with apatinib-containing therapy in our institution...Legal entity responsible for the study: Ruijin Hospital. Funding: Has not received any funding.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2402;
P=N/A
81572633 and 81972509). Clinical trial identification: NCT04260113 (7 February 2020).
- [VIRTUAL] A real world study of pyrotinib in patients with HER-2 positive/mutations tumors excluding breast cancer (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2286;
Legal entity responsible for the study: JunQian. Funding: Suzhou municipal health and family planning commission (GSWS2019019).
- AiTan (rivoceranib) / HLB Bio Group, paclitaxel / Generic mfg.
[VIRTUAL] A prospective study of apatinib in combination with neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2279;
P2
Funding: Has not received any funding. Clinical trial identification: Clinical trial information: NCT03857763.
- paclitaxel / Generic mfg.
[VIRTUAL] Changes in the tumour immune microenvironment in oesophageal squamous cell carcinoma patients receiving different neoadjuvant therapies (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2277;
Carboplatin combined with paclitaxel is administered as chemotherapy for three weeks per cycle (Q3W), 2 cycles...Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2231;
Legal entity responsible for the study: Jiangsu Cancer Hospital. Funding: Cancer Research Foundation of The Chinese Society of Clinical Oncology (Y-HR2016-025).
- AiTan (rivoceranib) / HLB Bio Group, paclitaxel / Generic mfg.
[VIRTUAL] Phase I study of apatinib plus POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2228;
P1
Funding: Jiangsu HengRui Medicine Co., Ltd. Clinical trial identification: NCT03244774.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] A prospective, multicenter, non-randomized, controlled trial of apatinib plus perioperative chemotherapy with FLOT protocol and surgery for the treatment of stage III gastric cancer (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2210;
Funding: Liaoning Natural Science Foundation. Clinical trial identification: ChiCTR-IIR-17012911.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Study on the safety and efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of non-operative oesophageal cancer (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2207;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- AiTan (rivoceranib) / HLB Bio Group, docetaxel / Generic mfg.
[VIRTUAL] Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: A prospective clinical study (data updated) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2204;
Funding: Beijing CSCO Clinical Oncology Research Foundation. Clinical trial identification: NCT: ChiCTR-OPC-17013834.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] A phase II study of neoadjuvant concurrent chemoradiotherapy with apatinib for HER-2 negative Siewert type II and III adenocarcinoma of esophagogastric junction (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2203;
P2, P3
Funding: Has not received any funding. Clinical trial identification: HRA-G01 11/21/2017.
- AiTan (rivoceranib) / HLB Bio Group, vinorelbine tartrate / Generic mfg.
[VIRTUAL] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2146;
We conducted this trial to investigate the efficacy and safety of apatinib (a TKI against VEGFR-2) plus EGFR-TKIs (including erlotinib, gefitinib, icotinib, afatinib and osimertinib) compared with chemotherapy for EGFR-TKI resistant NSCLC patients...27 patients received apatinib plus EGFR-TKI (apatinib in start dose of 250 mg plus original EGFR-TKI dose), 15 patients received chemotherapy (pemetrexed or vinorelbine with platinum)...Funding: Chinese Anti-Cancer Association. Clinical trial identification: ChiCTR-OIN-17012051.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2047;
P2
Funding: Jiangsu Hengrui Medicine Co., Ltd. Clinical trial identification: NCT03083041.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab in the treatment of patients with local advanced/metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, prospective, cohort study (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1833;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] PD1midKLRG1+Tbethigh effector memory T in the peripheral blood correlates with tumor response to combined therapy with lenvatinib and anti-PD-1 antibodies in unresectable hepatocellular carcinoma (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1808;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] A phase II study of camrelizumab for advanced hepatocellular carcinoma: Two-year outcomes and continued treatment beyond RECIST-defined progression (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1792;
P2
Ltd, China. Clinical trial identification: CTR20160871, Nov 14, 2016; NCT02989922, Dec 12, 2016.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1790;
P2
Funding: Jiangsu Hengrui Medicine Co., Ltd. Clinical trial identification: NCT03463876.
- AiTan (rivoceranib) / HLB Bio Group, capecitabine / Generic mfg.
[VIRTUAL] Efficacy and safety of apatinib combined with capecitabine in patients with advanced nasopharyngeal carcinoma (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1748;
Funding: Chinese Society of Clinical Oncology (CSCO)-Hengrui Clinical Oncology Research Fund. Clinical trial identification: CTR1800017229.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1426;
P2
Funding: Jiangsu Hengrui Medicine Co., Ltd. Clinical trial identification: NCT03558191; CTR20180865.